Compared with a statin alone, the addition of Praluent cost $308 000 per quality-adjusted life year (QALY) gained. But the addition of ezetimibe cost $81 000 per QALY compared with a statin alone.
Praluent-treated patients started the trial on 75 mg every 2 weeks, and 2,615 of them switched to 150 mg every 2 weeks because their LDL-C levels remained above 50 mg/dL.